ALIMERA SCIENCES INC - FORM 8-K - August 26, 2011

 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 23, 2011

ALIMERA SCIENCES, INC.
(Exact name of registrant as specified in its charter)

         
Delaware   001-34703   20-0028718
(State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)
     
6120 Windward Parkway
Suite 290
Alpharetta, Georgia
   30005
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (678) 990-5740

 
Not Applicable
(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

1

 

Item 5.02.   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On August 23, 2011, Bryce Youngren announced his intention to resign as a member of the Board of Directors (the “Board”) of Alimera Sciences, Inc. (the “Company”) and as a member of the Compensation Committee and Nominating/Corporate Governance Committee of the Board, effective as of August 26, 2011. James R. Largent, one of the Company’s current directors, has been appointed to serve as a member of the Compensation Committee and Nominating/Corporate Governance Committee of the Board following the effectiveness of Mr. Youngren’s resignation.

 

 

 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  ALIMERA SCIENCES, INC.
 		  
  By:   /s/ RICHARD S. EISWIRTH, JR.    
    Name:   Richard S. Eiswirth, Jr.   
    Title:   Chief Financial Officer and Chief
Operating Officer 		  
 
Dated: August 26, 2011

 

 

ALIMERA SCIENCES INC Reports